Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802201 · ClinicalTrials.gov registry record · Phase 2
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT03802201 is a Phase 2 study that has completed, run by Protagonist Therapeutics. The registered enrollment target is 63 participants.
The verdict
NCT03802201, a Phase 2 study, has completed, sponsored by Protagonist Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.
Interventions
- DRUG PTG-300
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-12-19 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03802201
The ClinicalTrials.gov registry entry for NCT03802201 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PTG-300 is the first listed.
NCT03802201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03802201 about?
NCT03802201 is a clinical study titled "Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia". This is a Phase 2 open-label, single-arm design study with dose escalation by subject cohort . The study is designed to monitor the PTG-300 safety profile, to obtain preliminary evidence of efficacy of PTG-300 for the treatment in β-thalassemia.
What is the current status of trial NCT03802201?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-12-19. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT03802201?
The interventions under investigation include: PTG-300 (DRUG).
Who is sponsoring clinical trial NCT03802201?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.